Condition: Multiple Myeloma · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23\~116 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma.
This description comes directly from the study's public registry record.
Serena Dong · 0512 69566088 · suhua.dong@innoventbio.com
Always discuss trial participation with your own doctor first.
| Wollongong Private Hospital | Wollongong, New South Wales, Australia | Suspended |
| Austin Hospital | Heidelberg, Victoria, Australia | Suspended |
| St Vincent's Hospital | Melbourne, Victoria, Australia | Suspended |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The first Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| Tongji Medical College of HUST Tongji Hospital | Wuhan, Hubei, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Not Yet Recruiting |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
| Jiangxi Cancer Hospital | Nanchang, Jiangxi, China | Not Yet Recruiting |
| ZhongShan Hospital FuDan University | Shanghai, Shanghai Municipality, China | Recruiting |
| The First Affiliated Hospital of XI'AN Jiaotong University | Xian, Shanxi, China | Not Yet Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06083207